Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Multiple Myeloma
Study Phase
Phase 3
Study Completion Date
January 2014
NCT00602641Uploaded 03-06-2018
Access via NCI by Request
PDS UID: nci-data-354
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
Files: NCT00602641-D3
Data DictionaryNCT00602641-D3-Data-Dictionary.pdf
Files: NCT00602641-D2
Data DictionaryNCT00602641-D2-Data-Dictionary.pdf
Files: NCT00602641-D1
Data DictionaryNCT00602641-D1-Data-Dictionary.pdf